BVF Inc. IL Buys 1,025,020 Shares of Regulus Therapeutics Inc (RGLS)
BVF Inc. IL increased its stake in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) by 7.9% during the 4th quarter, Holdings Channel reports. The fund owned 13,974,249 shares of the biopharmaceutical company’s stock after purchasing an additional 1,025,020 shares during the quarter. Regulus Therapeutics accounts for approximately 1.8% of BVF Inc. IL’s portfolio, making the stock its 17th largest position. BVF Inc. IL owned approximately 0.13% of Regulus Therapeutics worth $14,533,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. South Dakota Investment Council grew its position in Regulus Therapeutics by 37.1% during the 3rd quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after acquiring an additional 492,969 shares during the last quarter. Ascend Capital LLC bought a new position in Regulus Therapeutics during the 4th quarter worth approximately $1,053,000. Candriam Luxembourg S.C.A. bought a new position in Regulus Therapeutics during the 3rd quarter worth approximately $750,000. Goldman Sachs Group Inc. grew its position in Regulus Therapeutics by 189.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 240,890 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in Regulus Therapeutics by 18.2% during the 4th quarter. Victory Capital Management Inc. now owns 327,770 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 50,530 shares during the last quarter. Institutional investors and hedge funds own 53.72% of the company’s stock.
A number of brokerages have recently weighed in on RGLS. Chardan Capital reiterated a “neutral” rating on shares of Regulus Therapeutics in a research report on Tuesday, January 16th. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research report on Wednesday, January 24th. Leerink Swann began coverage on Regulus Therapeutics in a research report on Friday, January 5th. They issued an “outperform” rating and a $2.00 price objective on the stock. BMO Capital Markets set a $1.00 price objective on Regulus Therapeutics and gave the stock a “hold” rating in a research report on Thursday. Finally, Wedbush reiterated an “outperform” rating and issued a $4.00 price objective on shares of Regulus Therapeutics in a research report on Monday, December 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. Regulus Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $2.20.
Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.03. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative return on equity of 201.06% and a negative net margin of 99,868.07%. equities research analysts anticipate that Regulus Therapeutics Inc will post -0.55 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/03/11/bvf-inc-il-buys-1025020-shares-of-regulus-therapeutics-inc-rgls.html.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Want to see what other hedge funds are holding RGLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regulus Therapeutics Inc (NASDAQ:RGLS).
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.